Endocrinology and Cardiovascular Disease Center, National Center of Cardiology & Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Division of Diabetes Translation, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Diabetes Obes Metab. 2021 Oct;23(10):2385-2394. doi: 10.1111/dom.14481. Epub 2021 Jul 27.
The extent that pre-diabetic fasting plasma glucose (FPG) levels influence the effectiveness of lifestyle interventions in preventing type 2 diabetes (T2DM) is uncertain. We aimed to determine if the outcome of lifestyle intervention in people with impaired glucose tolerance (IGT) differs in those with normal or impaired FPG levels.
Data were used from the Da Qing Diabetes Prevention Outcome Study, which was a 30-year follow-up of a 6-year randomized trial of lifestyle intervention in 576 people with IGT. We then conducted a post-hoc analysis to compare the efficacy of intervention to reduce the incidence of T2DM and its complications in those with baseline FPG <100 mg/dL and FPG ≥100 mg/dL.
Lifestyle intervention reduced the cumulative incidence of T2DM by 37%-46% in those with baseline FPG <100 mg/dL and by 47%-51% in those with FPG ≥100 mg/dL. The FPG <100 mg/dL group had a lower cumulative incidence of diabetes and 6.41 years median delay in its onset compared with 2.21 years delay in the FPG ≥100 mg/dL group. In those with FPG <100 mg/dL intervention was associated with at least as great a reduction in cardiovascular disease and all-cause mortality as in the FPG ≥100 mg/dL group.
Lifestyle intervention reduced the incidence of T2DM in people with IGT regardless of baseline FPG levels, and in those with FPG <100 mg/dL led to a substantial delay in its onset. All persons with IGT, with normal or impaired FPG levels, may benefit from lifestyle intervention to delay its onset and mitigate the incidence of T2DM.
空腹血糖(FPG)处于糖尿病前期水平的程度对生活方式干预预防 2 型糖尿病(T2DM)的效果有何影响尚不确定。本研究旨在确定在葡萄糖耐量受损(IGT)人群中,FPG 水平正常或受损时,生活方式干预的结果是否存在差异。
本研究的数据来自大庆糖尿病预防结局研究,这是一项对 576 例 IGT 患者进行的为期 6 年的生活方式干预随机试验随访 30 年的研究。我们随后进行了一项事后分析,比较了基线 FPG<100mg/dL 和 FPG≥100mg/dL 的患者中,干预降低 T2DM 及其并发症发生率的效果。
在基线 FPG<100mg/dL 的患者中,生活方式干预降低了 37%-46%的 T2DM 累积发病率,在 FPG≥100mg/dL 的患者中降低了 47%-51%。与 FPG≥100mg/dL 组相比,FPG<100mg/dL 组的糖尿病累积发病率更低,发病中位时间延迟了 6.41 年,而 FPG≥100mg/dL 组仅延迟了 2.21 年。在 FPG<100mg/dL 的患者中,与 FPG≥100mg/dL 组相比,干预至少同样显著降低了心血管疾病和全因死亡率。
无论基线 FPG 水平如何,生活方式干预都降低了 IGT 患者的 T2DM 发生率,且在 FPG<100mg/dL 的患者中,T2DM 的发病时间显著延迟。所有 FPG 水平正常或受损的 IGT 患者,生活方式干预都可能有助于延迟其发病并减轻 T2DM 的发生率。